“Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents”, Hematol Meeting Rep, vol. 1, no. 6, Jun. 2009, doi: 10.4081/hmr.v1i6.675.